Complicated Recovery Awaits Victims Injured in Vegas Attack

LAS VEGAS (AP) — Their concert turned into a siege, and now their lives may become a battle. The staggering count of people injured in the shooting at a Las Vegas music festival means their recoveries are likely to be as varied as the victims themselves. Some injuries are as simple as broken bones, others gunshot wounds involving multiple surgeries and potential transplants, and all come with the added emotional scars of enduring the deadliest shooting in modern U.S. history, with 59 killed. At least 130 people remained hospitalized Tuesday, with 48 listed in critical condition. Hospitals said 185 others had already been released. At Sunrise Hospital and Medical Center alone, the count of those treated included 120 people who were struck by gunfire, a glimpse of the amount of ammunition unleashed in the attack. Rehabilitation for the most seriously hurt victims will take far longer than many may realize. "Years," said Dr. Thomas Scalea, physician-in-chief at the University of Maryland's Shock Trauma Center in Baltimore, one of the nation's largest trauma centers. "It's not days or weeks." Edward Leon raced to Las Vegas from Palm Springs, California, after learning his niece was shot in the stomach. He said he cried the whole way there. Although she survived an initial operation, he worries about what will come next. "She's out of surgery," he said, "but it's a long road ahead." At the site of the attack, people fashioned stretcher...
Source: JEMS: Journal of Emergency Medical Services News - Category: Emergency Medicine Authors: Tags: Major Incidents News Mass Casualty Incidents Patient Care Source Type: news

Related Links:

CONCLUSIONS Management by dedicated intensivists will improve not only the number of actual organ donors, but also the number of harvested organs. PMID: 30510153 [PubMed - in process]
Source: Annals of Transplantation - Category: Transplant Surgery Authors: Tags: Ann Transplant Source Type: research
Abstract PURPOSE OF REVIEW: There is great variability in how different organ allografts respond to the same tolerance induction protocol. Well known examples of this phenomenon include the protolerogenic nature of kidney and liver allografts as opposed to the tolerance-resistance of heart and lung allografts. This suggests there are organ-specific factors which differentially drive the immune response following transplantation. RECENT FINDINGS: The specific cells or cell products that make one organ allograft more likely to be accepted off immunosuppression than another are largely unknown. However, new insi...
Source: Current Opinion in Organ Transplantation - Category: Transplant Surgery Authors: Tags: Curr Opin Organ Transplant Source Type: research
Authors: Regard L, Martin C, Chassagnon G, Burgel PR Abstract Introduction Cystic fibrosis (CF) is a genetic disease that primarily affects the respiratory system and often leads to respiratory failure and premature death. Although pulmonary complications contribute to 85% of deaths, non-pulmonary complications are responsible for significant morbidity and mortality in adults with CF. Areas covered This review summarizes acute and chronic non-pulmonary complications in CF patients, with emphasis on emerging complications and in the context of the current growth and ageing of the CF adult population. It also address...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
We present a case of sirolimus-induced ILD that improved after discontinuation of sirolimus.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
The objective of this study was to compare skin cancer development between Caucasian and non-Caucasian transplant recipients at the University of Southern California.MethodsWe performed a retrospective chart review of lung and liver transplantations to determine the incidence of post-transplant skin cancer. Participants included patients who underwent lung or liver transplantation between 2005 and 2013 at our institution. Patients included in the study were limited to those who survived through the study observation period.ResultsWe analyzed 475 patients who underwent transplantation, including 370 liver transplant recipie...
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
Interactions with the bone marrow microenvironment (BMM) influence the pathophysiology of hematological malignancies. Reciprocally, hematological malignancies remodel the BMM in order to render it more hospitable for malignant progression. Hypothesizing that different leukemias differentially remodel stroma cells in the BMM, we tested differences in the expression of various genes in sorted osteoblastic cells from mice with B-cell acute lymphoblastic (B-ALL), acute myeloid (AML) or chronic myeloid leukemia (CML) or control mice by microarray. This revealed a high expression of various proteases, especially matrix metallopr...
Source: Blood - Category: Hematology Authors: Tags: 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: ALL Risk Associated Genes and Leukemia Infiltration Source Type: research
IntroductionMultiple myeloma (MM) is considered incurable but patients achieving minimal-residual disease (MRD) negative status following treatment have significantly better overall and progression-free survival. MM is highly heterogeneous both between and within patients, limiting the curative potential of novel agents targeting specific pathways. However all MM is highly sensitive to radiation. The α-emitter astatine-211 (211At) deposits a very large amount of energy (~100 keV/μm) within a few cell diameters (50-90 μm) resulting in irreparable double strand DNA breaks, making 211At, targeted to MM cells, part...
Source: Blood - Category: Hematology Authors: Tags: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I Source Type: research
This study focused on patients with SOT who were diagnosed with DLBCL-PTLD at Mayo Clinic (Rochester, MN). Patients were identified through the Mayo Clinic Lymphoma Data base and the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource (MER), between 1989 and 2017. The histology was re-reviewed (RLK) and classified according to the WHO Classification or Tumours of Haematopoietic and Lymphoid Tissues 2017. Cell of origin (COO) was performed by Hans algorithm. EBV RNA in situ hybridization (EBER) was performed. Cox proportional hazards models were used to assess the association of clinical factors in overall ...
Source: Blood - Category: Hematology Authors: Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Poster II Source Type: research
Conclusion:This study is the first to use an anti-CD33 monoclonal antibody for non-invasive immuno-PET-based imaging for AML detection, showing high sensitivity and specificity. This whole body imaging may be useful for AML diagnosis not only in the entire skeletal system, but also in the extramedullary organs, and for longitudinal monitoring of treatment response. Unlike conventional TBI, Image-guided fTMI along with conventional chemotherapy may result in an improved prognosis, as unintended major organs are spared from radiation.DisclosuresVallera: GT Biopharma: Consultancy, Research Funding. Stein: Celgene: Speakers Bu...
Source: Blood - Category: Hematology Authors: Tags: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II Source Type: research
Conclusion: PTLD is a heterogeneous group of immunodeficiency-associated lymphoproliferative disorders. The overall survival in non-destructive, polymorphic, and monomorphic PTLD were similar. Monomorphic T/NK cell types had inferior outcomes.Figure.DisclosuresMaurer: Morphosys: Research Funding; Nanostring: Research Funding; Celgene: Research Funding. Ansell: Celldex: Research Funding; Merck &Co: Research Funding; Takeda: Research Funding; LAM Therapeutics: Research Funding; Seattle Genetics: Research Funding; Trillium: Research Funding; Bristol-Myers Squibb: Research Funding; Affimed: Research Funding; Regeneron: Res...
Source: Blood - Category: Hematology Authors: Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Population Based Outcomes in Aggressive Lymphoma Source Type: research
More News: Emergency Medicine | Hospitals | Learning | Liver | Liver Transplant | Lung Transplant | Orthopaedics | Rehabilitation | Transplants | Universities & Medical Training | University of Maryland | Urology & Nephrology